Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

The main purpose of the study is to compare the change of the AZD5069 Pharmacokinetic profile when administered with ketoconazole. Subjects will be treated first with AZD5069 only followed by a washout period before starting with the combined treatment (both ketoconazole and AZD5069).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Ketoconazole

Criteria

Inclusion Criteria:

• Healthy male volunteers aged 18 to 50 years (inclusive).

• Veins suitable for cannulation or repeated venipuncture.

• Healthy volunteers with neutrophil counts within the laboratory normal reference range at Screening

• Body mass index (BMI) ≥18.0 and ≤30.0 kg/m2 calculated from height and weight at screening; minimum weight 50 kg and maximum weight 100 kg.

• Non-smokers or ex-smokers with no smoking history for the last 3 months prior to screening and a smoking history of less than 10 pack years (1 pack year = tobacco consumption corresponding to 20 cigarettes smoked per day for 1 year) at screening.

Exclusion Criteria:

• Healthy volunteers with latent tuberculosis as suggested by their history and judged by the Investigator

• Healthy volunteers who belong to a high-risk group for HIV infection.

• Known or suspected history of significant drug abuse as judged by the Investigator.

• History of alcohol abuse or excessive intake of alcohol as judged by the Investigator.

• Plasma donation within 1 month of screening or any blood donation/blood loss >500 mL during the 3 months and/or 1350 mL within the 12 months prior to screening.